Long-term Outcome of Patients With a Negative Work-up for Asymptomatic Microhematuria

Urology

Volumn 75, Issue 1, 2010, Pages 20-25

  Madeb, Ralph ^a   Golijanin, Dragan ^a   Knopf, Joy ^a   Davis, Matthew ^a   Feng, Changyong ^a   Fender, Anne ^a   Stephenson, Laura ^b   Messing, Edward M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Bureau of Health Information and Policy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ADULT; ARTICLE; BLADDER CANCER; BLOOD CELL COUNT; BLOOD CLOTTING; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CYSTOSCOPY; DEATH CERTIFICATE; FOLLOW UP; HEMATURIA; HUMAN; INTRAVENOUS UROGRAPHY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; URINALYSIS; URINARY TRACT CANCER; URINE CULTURE; URINE CYTOLOGY;

ALGORITHMS; HEMATURIA; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 72249118427     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.107     Document Type: Article

References (24)

1. Cohen R.A., and Brown R.S. Clinical practice. Microscopic hematuria. N Engl J Med 348 (2003) 2330-2338
2. Grossfeld G.D., Litwin M.S., Wolf Jr. J.S., et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy-part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 57 (2001) 604-610
3. Grossfeld G.D., Litwin M.S., Wolf J.S., et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy-part I: definition, detection, prevalence, and etiology. Urology 57 (2001) 599-603
4. Grossfeld G.D., Wolf Jr. J.S., Litwan M.S., et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 63 (2001) 1145-1154
5. US Preventive Services Task Force. Guide to Clinical Preventive Services (1996), Office of Disease Prevention and Health Promotion, Washington, DC
6. Nabi G., Greene D., and O'Donnell M.O. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up?. J Clin Pathol 57 (2004) 365-368
7. Messing E.M., and Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 32 (1990) 838-845
8. Hiatt R.A., and Ordonez J.D. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev 3 (1994) 439-443
9. Howard R.S., and Golin A.L. Long-term follow up of asymptomatic microhematuria. J Urol 145 (1991) 335-336
10. Khadra M.H., Pickard R.S., Charlton M., et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 163 (2000) 524-527
11. Messing E.M., Madeb R., Young T., et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107 (2006) 2173-2179
12. Messing E.M., Young T.B., Hunt V.B., et al. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol 137 (1987) 919-922
13. Messing E.M., Young T.B., Hunt V.B., et al. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer 64 (1989) 2361-2367
14. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106
15. Johnson E., Daignault S., Zhang Y., et al. Gender disparities in urologic referral of hematuria. J Urol 175 suppl 4 (2006) 286
16. Messing E.M. Urothelial tumors of the bladder. In: Wein A.J., Kavoussi L.R., and Novick A.C. (Eds). Campbell-Walsh Urology (2007), W.B. Saunders, Philadelphia, PA 2407-2445 Chapt.75
17. Lotan Y., Svatek R.S., and Sagalowsky A.I. Should we screen for bladder cancer in a high-risk population?. A cost per life-year saved analysis. Cancer 107 (2006) 982-990
18. Grossman H.B., Messing E., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-815
19. Grossman H.B., Soloway M., Messing E., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299-305
20. Boman H., Hedelin H., Holmang S., et al. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 167 suppl 4 (2002) 80-83
21. Messing E.M. Bladder tumor markers. J Urol 175 (2006) 1195-1196
22. Messing E.M. Urothelial tumors of the urinary tract. In: Walsh P.C., Retik A.B., Vaughan Jr. E.D., and Wein A.J. (Eds). Campbell's-Walsh Urology (2007), WB Saunders, Philadelphia, PA
23. Fisher M. Use and analysis of data-an evaluation of the Wisconsin Cancer Reporting System's completeness of case reporting (1982), Wisconsin Department of Health and Social Services, Madison, WI
24. Evans C.P. Evidence-based medicine for the urologist. BJU Int 94 (2004) 1-2